- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
TeraRecon Launches AI-Driven Neuroimaging Platform
TeraRecon Neuro reportedly offers six automated and customizable computed tomography (CT) perfusion maps that facilitate assessment of brain function in hemorrhagic and ischemic neurological cases.
A new artificial intelligence (AI)-powered neuroimaging platform may offer adjunctive benefits for timely assessment and treatment decisions in neurovascular emergencies.
One of the benefits of TeraRecon Neuro is automated screening for challenging cases involving possible intracerebral hemorrhages (ICHs) and large vessel occlusions (LVOs), according to TeraRecon, the manufacturer of the platform.
The company said TeraRecon Neuro enables radiologists to modify the platform’s algorithm to optimize AI outputs. TeraRecon noted the TeraRecon Neuro platform, viewable on diagnostic desktop viewers and via a mobile app, also enhances the assessment of brain function with six customizable computed tomography (CT) perfusion maps.
“We believe the best use case scenario is not autonomous AI, but rather expert clinical supervision that is augmented by AI-driven insights. TeraRecon Neuro was designed to accommodate all care team members and workflows, while simultaneously maintaining standardization across the care continuum to ensure timely delivery of coordinated care for numerous neurovascular emergencies,” noted Dan McSweeney, the president of TeraRecon.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
